Skip to main content

Table 5 Main features of not-for-profit and profit trials ended between 2008 and 2015

From: Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar

ClinicalTrials.gov studies

Not-for-profit 2008–2015 (274)

Profit 2008–2015 (224)

 

N

%

N

%

Study phase

 0

3

16.5

 I

46

19.0

73

33.2

 I-II

18

7.4

15

6.8

 II

103

42.6

96

43.6

 II-III

4

1.8

 III

29

12.0

17

7.7

 IV

3

1.2

2

0.9

 Observational

40

16.5

13

5.9

 Missing

32

 

4

 

Center

 Multicenter

125

58.7

162

78.6

 Single-center

88

41.3

44

21.4

 Missing

61

 

18

 

Country

 America

178

66.4

116

53.5

 Europe

64

23.9

25

11.5

 International

16

6.0

66

30.4

 Asia

8

3.0

9

4.2

 Oceania

2

0.8

1

0.5

Study purpose

 Treatment

196

76.0

203

92.7

 Prevention and screening

10

3.9

4

1.8

 Diagnostic

8

3.1

5

2.3

 Supportive care

15

5.8

2

0.9

 Health services research

3

1.2

1

0.5

 Other

26

10.1

4

1.8

 Missing

16

   

Endpoint classification

 Efficacy

71

32.0

30

14.4

 Safety

18

8.1

35

16.8

 Safety and efficacy

78

35.1

110

52.9

 Other

55

24.8

33

15.9

 Missing

52

 

16

 

Study duration (years) - Mean (SD)

5.27 (3.00)

 

3.74 (2.17)

 

Number of subjects

  < 50

128

46.7

112

50.0

  > =50

143

52.2

111

49.5